Altimmune

ALT Lead: Phase 3 ★ Read the deep dive → 12 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-15

Catalyst timeline

pemvidutide MASH Ph3 start2026pemvidutide MASH Ph3 start, 2026, routine
pemvidutide AUD Ph2 topline2H 2027pemvidutide AUD Ph2 topline, 2H 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

pemvidutide

ALT-801

Peptide Target: GLP-1 receptor, glucagon receptor, GLP-1, glucagon

Metabolic Dysfunction-Associated Steatohepatitis Phase 3 subcutaneous NCT04561245
Alcohol Use Disorder Phase 2 subcutaneous NCT06987513
Alcohol-Associated Liver Disease Phase 2 subcutaneous NCT07009860

Biotech Distilled coverage (12)

2026-08-13 UPDATE: Altimmune (ALT) - The Q2 Print Quietly Moves a Catalyst 🔒 Paid
2026-08-04 UPDATE: Altimmune (ALT) - PERFORMA Is Live, and the Protocol Answers the Tolerability Question 🔒 Paid
2026-07-28 UPDATE: Altimmune (ALT) - The 2.4 mg Dose Just Answered the Question I Asked in December 🔒 Paid
2026-05-27 UPDATE: Altimmune (ALT) - The Biopsy Data Finally Shows Up
2026-05-02 UPDATE: Altimmune (ALT) - The Second Whale Surfaces 🔒 Paid
2026-05-01 UPDATE: Altimmune (ALT) - Deep Track Just Showed Its Cards 🔒 Paid
2026-04-27 UPDATE: Altimmune (ALT) - The $4.40 Floor Just Became a $3.00 Ceiling 🔒 Paid
2026-03-21 UPDATE: Altimmune (ALT) - 400 Million Shares?
2026-03-07 UPDATE: Altimmune (ALT) - The $340M War Chest and the Phase 3 Blueprint
2026-01-30 UPDATE: Altimmune (ALT) – The Smart Money Bailout
2026-01-05 UPDATE: The FDA Just Blinked (In a Good Way) – Altimmune Derisked?
2025-12-19 Altimmune, Inc. (ALT): Scientific Due Diligence for Lead and Pipeline Indications

Articles open on Substack. Some deep dives are subscriber-only.